Drug Database
Back to search

Belgium· BE-AMP-SAM061896-00

Depo-Provera 150 mg/ml

A medroxyprogesterone product containing medroxyprogesterone acetate, registered in Belgium by Pfizer. The same ATC class is registered in 11 of our 19 countries.

ATC G03AC06

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedDepo-Provera 150 mg/mlATCG03AC06REGISTER NO.BE-AMP-SAM061896-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about medroxyprogesterone acetateAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Medroxyprogesterone is registered in 11 of 19 countries.

Countries holding a registration under ATC G03AC06 (medroxyprogesterone), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 7 of them publish a price we can compare per daily dose
Search medroxyprogesterone products by name

Medroxyprogesterone · ATC G03AC06

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Medroxyprogesterone Acetate
Manufacturer
Pfizer
Country
Belgium (BE)
ATC code
G03AC06
ATC class
Medroxyprogesterone
Defined daily dose
1.67 mg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

1 priced
  • be_apb
    0108423
    EUR 10.46
  • be_apb
    0704593

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

245 interactions on record for medroxyprogesterone.

Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check medroxyprogesterone against other medicinesHow interaction checks work

Medroxyprogesterone · interactions on record

245 records

  • 21 severe
  • 213 moderate
  • 7 minor

Most severe, free to view

  • Tranexamic acidB02AA02severe
  • BosentanC02KX01severe
  • GriseofulvinD01AA08severe
  • GriseofulvinD01BA01severe

4 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Medroxyprogesterone in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All medroxyprogesterone products

Authorised across Europe · EMA

The same active substance is authorised in 22 EEA countries. Names it is sold under:

  • Austria · Depocon, Farlutal
  • Bulgaria · Фарлутал
  • Czechia · Depo-Provera, Provera
  • Germany · Depo-Clinovir, Mpa
  • Denmark · Depo-Provera, Provera
  • Estonia · Farlutal
  • Spain · Depo-Progevera, Progevera
  • Finland · Farlutal, Provera
  • France · Depo Prodasone, Depo Provera
  • United Kingdom (Northern Ireland) · Depo-Provera, Medroxyprogesterone Acetate Pfizer
  • Croatia · Provera
  • Hungary · Depo-Provera, Provera
  • Ireland · Depo-Provera, Provera
  • Iceland · Depo-Provera
  • Italy · Depo-Provera, Farlutal
  • Luxembourg · Depo-Provera, Provera
  • Latvia · Depo-Provera
  • Netherlands · Depo-Provera, Provera
  • Norway · Depo-Provera, Provera
  • Poland · Depo-Provera, Provera
  • Portugal · Depo-Provera 150
  • Sweden · Depo-Provera, Provera

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/85eb376e-894d-4a54-919f-1d5006346416
GET /v1/drugs/85eb376e-894d-4a54-919f-1d5006346416?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Suspension for injection",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Depo-Provera 150 mg/ml",
  "name_fr": "Depo-Provera 150 mg/ml",
  "name_nl": "Depo-Provera 150 mg/ml",
  "amp_code": "SAM061896-00",
  "strengths": [
    "150.0000",
    "1.3500",
    "0.1500",
    "8.6000",
    "2.4000"
  ],
  "pack_count": 2,
  "substances": [
    "Medroxyprogesterone Acetate",
    "Methyl Parahydroxybenzoate",
    "Propyl Parahydroxybenzoate",
    "Sodium Chloride",
    "Sodium Hydroxide",
    "Polysorbate 80"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Medroxyprogesterone",
  "authorisation_numbers": [
    "BE061896"
  ]
}
API referenceMCP serverPlans

See everything about medroxyprogesterone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console